Zehra Kaymakcalan
34Patents
21h-index
54Co-inventors
88Inventor score
Filing activity: May 14, 1991 → Jan 28, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6090382A | Human antibodies that bind human TNF.alpha. | Emerging Cross-Sectional Technologies | 444 | Expired |
| US6258562A | Human antibodies that bind human TNF.alpha. | Emerging Cross-Sectional Technologies | 307 | Expired |
| US6914128B1 | Human antibodies that bind human IL-12 and methods for producing | Chemistry; Metallurgy | 292 | Expired |
| US6509015B1 | Human antibodies that bind human TNFa | Emerging Cross-Sectional Technologies | 211 | Expired |
| US7223394B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 160 | Expired |
| US7541031B2 | Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 147 | Active |
| US7588761B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 143 | Expired |
| US8414894B2 | Human antibodies that bind human TNFα and methods of using same | Emerging Cross-Sectional Technologies | 73 | Active |
| US8206714B2 | Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa | Emerging Cross-Sectional Technologies | 72 | Active |
| US8197813B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 71 | Active |
| US8372401B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 70 | Active |
| US8372400B2 | Methods of treating disorders using human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 69 | Active |
| US7883704B2 | Methods for inhibiting the activity of the P40 subunit of human IL-12 | Chemistry; Metallurgy | 62 | Active |
| US7504485B2 | Human antibodies that bind human IL-12 | Chemistry; Metallurgy | 62 | Expired |
| US5166133A | Method for inhibing adhesion of white blood cells to endothelial cells | Chemistry; Metallurgy | 58 | Expired |
| US5340800A | Peptide medicaments for the treatment of disease | Human Necessities | 49 | Expired |
| US8753633B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 49 | Active |
| US7491516B2 | Dual specificity antibodies and methods of making and using | Chemistry; Metallurgy | 46 | Expired |
| US8921526B2 | Mutated anti-TNFα antibodies and methods of their use | Chemistry; Metallurgy | 34 | Active |
| US9085618B2 | Low acidic species compositions and methods for producing and using the same | Chemistry; Metallurgy | 32 | Active |
| US9266949B2 | Low acidic species compositions and methods for producing and using the same | Chemistry; Metallurgy | 24 | Active |
| US9200070B2 | Low acidic species compositions and methods for producing and using the same | Chemistry; Metallurgy | 20 | Active |
| US9181337B2 | Modulated lysine variant species compositions and methods for producing and using the same | Chemistry; Metallurgy | 19 | Active |
| US9200069B2 | Low acidic species compositions and methods for producing and using the same | Chemistry; Metallurgy | 17 | Active |
| US8969024B2 | Compositions and methods comprising binding proteins for adalimumab | Emerging Cross-Sectional Technologies | 16 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.